Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD4 | P21917 | 5/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175239 | 0.94 | HTR1B (0.40) | HTTCYP3A4SMN1; SMN2DRD2DRD4 | |
| SCHEMBL31704177 | 0.92 | ALDH1A1 (0.42) | HTTCYP3A4SMN1; SMN2 | |
| SCHEMBL553453 | 0.92 | HTT (0.51) | HTTCYP3A4SMN1; SMN2DRD2DRD4 | |
| SCHEMBL31682488 | 0.91 | KDM4E (0.41) | HTTCYP3A4SMN1; SMN2DRD2DRD4 | |
| SCHEMBL4398294 | 0.88 | ALDH1A1 (0.42) | DRD2DRD4DRD3 | |
| SCHEMBL31618578 | 0.88 | LTA4H (0.42) | HTTCYP3A4SMN1; SMN2SMYD2 | |
| SCHEMBL29135908 | 0.88 | SIGMAR1 (0.45) | HTTDRD2DRD4DRD3 | |
| SCHEMBL553963 | 0.88 | HTR1B (0.46) | HTTCYP3A4SMN1; SMN2SMYD2GAA | |
| SCHEMBL18286159 | 0.86 | ALDH1A1 (0.41) | HTTCYP3A4SMN1; SMN2SMYD2GAA | |
| SCHEMBL21878235 | 0.86 | CYP3A4 (0.40) | HTTCYP3A4SMN1; SMN2SMYD2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400491-A1 | NOVEL LIPIDS USED FOR NUCLEIC ACID DELIVERY AND LIPID NANOPARTICLE COMPOSITION | Themedium Therapeutics Co., Ltd (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240158352-A1 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | CAN-THERAPY INC. (KR) | 2024-05-16 | — | — | US | disclosed |
| WO-2022182187-A1 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2022-09-01 | — | — | WO | disclosed |
| EP-2601177-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2017-10-18 | — | — | EP | disclosed |
| US-20160176906-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-06-23 | — | — | US | disclosed |
| US-9248140-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-02-02 | — | — | US | disclosed |
| US-20150328239-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2015-11-19 | — | — | US | disclosed |
| US-9018381-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-04-28 | — | — | US | disclosed |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (UK) | 2013-11-21 | — | — | US | disclosed |
| EP-2601177-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | AstraZeneca AB (SE) | 2013-06-12 | — | — | EP | disclosed |
| US-8329681-B2 | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals | UNIVERSITY OF MASSACHUSETTS (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017251-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | WO | disclosed |
| EP-1940775-A2 | METHODS AND COMPOSITIONS FOR THE EFFICIENT DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND ANIMALS | University of Massachusetts (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070260055-A1 | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-08 | — | — | US | disclosed |
| WO-2007022030-A2 | METHODS AND COMPOSITIONS FOR THE EFFICIENT DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND ANIMALS | UNIVERSITY OF MASSACHUSETTS (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1019361-B1 | POLYFUNCTIONAL CATIONIC CYTOFECTINS, FORMULATIONS AND METHODS FOR GENERATING ACTIVE CYTOFECTIN:POLYNUCLEOTIDE TRANSFECTION COMPLEXES | UNIV CALIFORNIA (US) | 2004-04-14 | — | — | EP | disclosed |
| US-5925623-A | COMPLEXES OF POLYNUCLEOTIDES WITH CATIONIC TRANSPORTER MOLECULES THAT FACILITATE DELIVERY THROUGH MEMBRANE STRUCTURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-07-20 | — | — | US | disclosed |
| US-5869715-A | Polyfunctional cationic cytofectins | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-02-09 | — | — | US | disclosed |
| US-5824812-A | DRUG DELIVERY WITH AN AMINE SALT OR AMINE QUATERNIZED COMPOUND; CATIONIC TRANSFECTION AMPHIPHILES FOR GENE THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070260055-A1 | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals | ABCB4, PIGS, CETP | HTT 678/4885CYP3A4 4328/4885SMN1; SMN2 754/4885 |
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | HTT 3192/4885CYP3A4 1309/4885SMN1; SMN2 4406/4885 |
| US-20240158352-A1 | NOVEL ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | DPP4, ADAMTS4, DPP3 | HTT 1588/4885CYP3A4 364/4885SMN1; SMN2 3600/4885 |
| US-20150328239-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTT 3192/4885CYP3A4 1309/4885SMN1; SMN2 4406/4885 |
| US-20160176906-A1 | Chemical Compounds | BCL2, BCL2L1, BAX | HTT 3192/4885CYP3A4 1309/4885SMN1; SMN2 4406/4885 |
| US-20130310344-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BCL2, BAX, BCLAF1 | HTT 3761/4885CYP3A4 3076/4885SMN1; SMN2 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.